EGFR mutation is the most well-established driver mutation and the most important drug target in NSCLC that comprises approximately 85% of all lung cancer, and it was found a high EGFR mutation frequency (51.4% overall) in the tumors from Asian NSCLC patients 2. This evidence concerns the gene EGFR and non-small cell lung carcinoma.